Project description:Purpose:Assess the difference in gene expression of taxol-resistant TNBC cells relative to parental cells (MDA-MB-436 and HS 578t) Methods: RNA-seq was performed on paclitaxel-treated MDA-MB-436 cells that are resistant to Paclitaxel (R20A, R20B, R20C) and in control-treated (DMSO) parental MDA-MB-436 cells that are sensitive to Paclitaxel (DMSO) Results: We mapped about 20 million sequence reads per sample to the human genome (hg19) and identified identified differentially expressed genes Conclusions: Our study identified genes significantly enriched or repressed in taxol-resistant cells relative to parental cells in both TNBC models (MDA_MB-436 and HS 578T)
Project description:To investigate the gene targets associated with paclitaxel resistance in EOC, we cultured A2780 and paclitaxel resistant A2780 (A2780-Taxol) cell lines.
Project description:cSBL is a multifunctional protein that has lectin and ribonuclease activity, and show selective cytotoxicity against many kinds of cancer cells.For further understanding anti-tumor effects of cSBL, we treated cSBL-sensitive malignant mesothelioma H28 cells with cSBL consecutively, and established cSBL-resistant (cSR) cells. We have established 5 resistant clones and using two clones that show higher resistant rates, microarray analysis was performed to identify significant altered gene expression upon cSBL-sensitive and -cSR cell lines.
Project description:Purpose:Assess the difference in gene expression of taxol-resistant TNBC cells relative to parental cells (MDA-MB-436 and HS 578T) upon treatment with UNC1999 3uM Conclusions: Our study identified genes significantly enriched or repressed in taxol-resistant cells relative to parental cells in both TNBC models (MDA_MB-436 and HS 578T)
Project description:Purpose:Assess the reprogramming of H3K4me1, H3K4me3, H3K27ac and H3K27me3 in paclitaxel-resistant triple-negative breast cancer cells relative to paclitaxel-sensitive cells Methods: ChIP-seq was performed on paclitaxel-treated MDA-MB-436 cells that are resistant to Paclitaxel (R20A, R20B, R20C) and in control-treated (DMSO) parental MDA-MB-436 cells that are sensitive to Paclitaxel (DMSO) Results: Using we mapped about 20 million sequence reads per sample to the human genome (hg19) and identified significant peaks in each cell lines using MACS.2.0 tool. Conclusions: Our study identified major reprogramming of H3K27me3 in the taxol-resistant TNBC cells relative to parental (TNBC cells), with loss of discrete H3K27me3 peaks in the resistant cells concomittent to acquisition of clusters of H3K27me3.
Project description:Altered expression of miRNAs has been demonstrated in tumor tissue and plasma/serum of cancer patients. miRNAs have been shown to have both diagnostic and prognostic significance and to potentially constitute novel targets and therapeutic agents for cancer treatment. Experimental evidences also support a role of miRNAs in tumor cell response to therapy, including resistance to BRAF inhibitors (BRAFi) in melanoma. In this study, miRNA expression pattern was determined in a BRAFV600E melanoma cell line sensitive to the BRAFi dabrafenib (i.e A375) and in its drug-resistant counterpart (i.e. A375R), derived in vitro by culturing the sensitive cell line with progressively increasing concentrations of dabrafenib (from 8 nM to 1.5 mM).
Project description:To investigate the differences in gene expression between parental SKOV3 cells and the two taxol-resistant cell lines SKOV3/Tx50 and SKOV3/Tx600.
Project description:To investigate the differences in gene expression between parental SKOV3 cells and the two taxol-resistant cell lines SKOV3/Tx50 and SKOV3/Tx600.
Project description:To investigate the differences in gene expression between parental SKOV3 cells and the two taxol-resistant cell lines SKOV3/Tx50 and SKOV3/Tx600.
